David R. Knop

Biography

Since AGTC’s inception, Dr. Knop has been responsible for the development of all upstream and downstream unit operations comprising the company’s proprietary rHSV co-infection method for rAAV manufacture. Dr. Knop joined AGTC in 2002 after completing his doctoral research in Chemical Engineering at Michigan State University which focused on biocatalytic production of value-added pharmaceutical intermediates useful in the synthesis of anti-influenza medicinals. He has defined, and executed technology transfer on, multiple phase 1 and 2 clinical material generation processes for rHSV raw material and rAAV clinical trial material to contract manufacturing organizations, academic and corporate partners. Dr. Knop has authored dozens of manuscripts, presentations, and posters encompassing the production, processing, and purification of rHSV and rAAV vectors for use in gene therapy applications. 

Research Interest

He focused on biocatalytic production of value-added pharmaceutical intermediates useful in the synthesis of anti-influenza medicinals.